



Canadian
Cancer Clinical
Trials Network

Canadian Cancer Clinical Trials Network

Quarterly Performance Report

Quarter 1, FY 2019/20 (Year 6): April 1 – June 30, 2019


Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials	2
Patient Recruitment at All Network Sites	2
Number of patients recruited and number of Portfolio trials per Network site (by fiscal year)	3
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba	3
Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba	4
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario.....	5
Number of active recruiting 3CTN Portfolio trials – Ontario.....	6
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec	7
Number of Active Recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec	8
Section B: 3CTN Portfolio Metrics.....	9
Active Recruiting Portfolio Trials by Disease Site and Phase	9
Portfolio Impact Assessment.....	10
Overview of Portfolio Applications – Process Efficiency	11
Appendix: Additional Notes	12
Table: Study Impact Criteria Definitions	12

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years



Notes:

- 986 patients were recruited to Portfolio trials in Quarter 1. Y6 target is to achieve 60% above pre-3CTN baseline.
- Q1 accrual of 986 patients fell short of the Q1 target of 992 patients for the Network overall.
- The TMIST trial being conducted by 2 Ontario Cancer Centers and 1 Quebec cancer centre contributed 259 (28%) patients to the Network total recruitment during this period.

Number of patients recruited and number of Portfolio trials per Network site (by fiscal year)

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y2	Y3	Y4	Y5	Y6Q1 2019-20	% of Y6 Baseline
CancerCare Manitoba	99	72	102	90	98	16	16%
Prairie Mountain Health	1	0	0	0	1	0	0%
CancerCare Manitoba - Pediatrics	18	20	14	17	4	0	6%
Manitoba	118	92	116	107	103	16	14%
BC Cancer Agency - Vancouver Centre	106	117	152	127	107	29	27%
Abbotsford Centre	16	28	14	22	22	0	0%
Centre for the North, Prince George	1	6	4	8	9	5	500%
Sindi Ahluwalia Hawkins Centre for the Southern Interior	38	40	30	28	38	10	26%
Vancouver Island Centre	26	44	69	64	69	18	115%
British Columbia Cancer Agency	187	235	269	249	245	62	57%
Alberta Health Services, Cross Cancer Institute	102	112	137	99	103	20	35%
Alberta Health Services, Tom Baker Cancer Centre	76	140	125	154	139	31	59%
Alberta Health Services	178	252	262	253	242	51	166%
Western Region Total	483	579	647	609	590	67	14%

Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y5Q1 2018-19	Y5Q2 2018-19	Y5Q3 2018-19	Y5Q4 2018-19	Y6Q1 2019-20
CancerCare Manitoba	37	28	27	29	23	22
Prairie Mountain Health	0	0	0	1	1	1
CancerCare Manitoba - Pediatrics	19	17	17	15	13	10
BC Cancer Agency - Vancouver Centre	50	25	25	27	27	26
Abbotsford Centre	6	4	4	4	4	5
Centre for the North, Prince George	2	3	3	3	3	2
Sindi Ahluwalia Hawkins Centre for the Southern Interior	23	9	10	6	6	5
Vancouver Island Centre	12	5	6	5	5	8
Alberta Health Services, Cross Cancer Institute	29	29	28	30	29	27
Alberta Health Services, Tom Baker Cancer Centre	20	29	32	32	30	30

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario

Network Site	Pre-3CTN Baseline	Y2	Y3	Y4	Y5	Y6Q1 2019-20	% of Y6 Baseline
London Health Sciences Centre	186	172	187	169	248	66	35%
Grand River Regional Cancer Centre	20	13	43	32	34	2	10%
Windsor Regional Cancer Centre	14	17	63	32	16	0	0%
Hamilton Health Sciences, Juravinski Cancer Centre	181	231	247	454	345	65	36%
Cambridge Memorial Hospital	11	2	5	4	5	1	9%
St. Joseph's Healthcare Hamilton	21	30	54	74	40	9	43%
Walker Family Cancer Centre, Niagara Health System	17	22	13	23	37	17	100%
Sunnybrook Health Sciences Centre, Sunnybrook Research Institute	141	229	398	363	651	155	110%
Humber River Hospital	1	2	1	9	7	0	0%
Michael Garron Hospital (Toronto East General Hospital)	2	2	1	7	2	0	0%
Princess Margaret Cancer Centre	396	384	533	473	720	121	31%
Markham Stouffville Hospital	1	0	28	9	2	2	200%
Mount Sinai Hospital	21	12	40	7	12	2	10%
Northeast Cancer Centre - Health Sciences North	24	17	12	9	18	0	8%
North York General Hospital	1	4	8	11	9	0	100%
Royal Victoria Regional Health Centre	8	18	58	23	9	1	13%
Southlake Regional Health Centre	10	15	75	26	68	8	80%
St. Michael's Hospital	19	0	27	2	1	0	0%
Thunder Bay Regional Health Sciences Centre	26	3	46	16	25	2	8%
Trillium Health Partners	27	5	51	10	12	2	7%
William Osler Health System	1	0	29	13	0	1	100%
The Ottawa Hospital Cancer Centre	132	238	396	500	850	216	164%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	58	122	84	72	22	54%
Lakeridge Health, RSM Durham Regional Cancer Centre	22	26	70	18	15	8	36%
Ontario Subtotal	1,323	1,500	2,507	2,368	3198	700	53%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y5Q1 2018-19	Y5Q2 2018-19	Y5Q3 2018-19	Y5Q4 2018-19	Y6Q1 2019-20
London Health Sciences Centre	79	45	46	46	40	47
Grand River Regional Cancer Centre	11	8	8	8	8	6
Windsor Regional Cancer Centre	4	4	4	5	5	4
Hamilton Health Sciences, Juravinski Cancer Centre	51	29	27	30	32	22
Cambridge Memorial Hospital	5	2	2	3	2	2
St. Joseph's Healthcare Hamilton	2	3	2	2	3	1
Walker Family Cancer Centre, Niagara Health System	10	8	7	8	7	6
Sunnybrook Health Sciences Centre, Sunnybrook Research Institute	10	32	34	34	35	34
Humber River Hospital	0	3	3	2	2	2
Michael Garron Hospital (Toronto East General Hospital)	3	2	2	2	2	1
Princess Margaret Cancer Centre	91	71	74	81	86	78
Markham Stouffville Hospital	0	0	0	1	1	1
Mount Sinai Hospital	6	4	4	4	4	4
Northeast Cancer Centre - Health Sciences North	10	6	7	7	8	7
North York General Hospital	0	3	4	3	3	3
Royal Victoria Regional Health Centre	5	8	6	6	6	6
Southlake Regional Health Centre	3	9	10	10	10	9
St. Michael's Hospital	4	1	1	1	2	2
Thunder Bay Regional Health Sciences Centre	8	5	5	5	5	5
Trillium Health Partners	9	3	3	3	4	4
William Osler Health System	0	1	1	2	2	1
The Ottawa Hospital Cancer Centre	56	38	37	41	51	41
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	26	25	25	26	21
Lakeridge Health, RSM Durham Regional Cancer Centre	13	3	4	3	3	3

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y2	Y3	Y4	Y5	Y6Q1 2019-20	% of Y6 Baseline
Nova Scotia Health Authority	39	40	52	45	42	7	18%
Eastern Regional Health Authority	15	4	12	8	15	3	20%
Janeway Child Health Centre	4	3	4	4	0	0	0%
Atlantic total	58	47	68	57	57	10	17%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	83	161	149	66	40	46%
CISSS de l'Outaouais	3	0	4	32	1	0	0%
CHU de Québec – Université Laval, adults	180	25	144	236	99	42	23%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	46	16	70	55	18	18	39%
Centre Hospitalier de l'Université de Montréal (CHUM)	153	59	123	149	112	20	13%
CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM)	3	0	4	16	8	2	67%
CIUSSS de l'Est-de-l'Île-de-Montréal(CIUSSS-EDIM)	60	12	51	49	23	7	12%
CHU de Quebec - Pediatrics	17	14	7	17	22	5	29%
Centre hospitalier universitaire de Sainte-Justine	42	26	44	40	38	12	29%
Montreal Children's Hospital	24	23	14	20	8	1	4%
Quebec Clinical Research Organization in Cancer (Q-CROC)	615	258	622	763	395	147	24%
Eastern Region Total	673	305	690	820	452	157	23%


Number of Active Recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y5Q1 2018-19	Y5Q2 2018-19	Y5Q3 2018-19	Y5Q4 2018-19	Y6Q1 2019-20
Nova Scotia Health Authority	14	12	16	17	17	19
Eastern Regional Health Authority	6	4	6	5	6	8
Janeway Child Health Centre	5	11	9	9	9	5
CISSS de l'Outaouais	1	1	1	1	2	2
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	-	-	-	-	18
CHU de Québec – Université Laval, adults	39	19	20	26	26	26
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	10	13	11	13	16	16
Centre Hospitalier de l'Université de Montréal (CHUM)	28	32	34	37	37	33
CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM)	4	2	2	2	2	2
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS-EDIM)	6	12	13	11	10	10
CHU de Quebec - Pediatrics	11	13	16	17	15	17
Centre hospitalier universitaire de Sainte-Justine	9	30	22	22	24	17
Montreal Children's Hospital	5	25	25	20	21	12

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



*as of September 3, 2019

Portfolio Impact Assessment

Objective: To provide a more specific and translatable impact description of 3CTN Portfolio trials for existing and future stakeholders.

Active Recruiting Portfolio trials, N=173

Trial Categories of Interest	Breakthrough trial	Platform trial	Enhancement/derivative trial	Sustaining trial	Cross cancer trial	N/A	Total # of Trials per Study Criteria
Novel therapy	10	15	5		3		30
Rare cancer setting	3	29	9	8	1	1	50
Patient management		50	5	21	6	2	78
Precision medicine	8	40	17	4	5	2	71
Vulnerable populations		18	5	8	1		31
Lifestyle Interventions		7		1			8
N/A		7					7
Total # of Trials per Study Criteria	10	114	19	28	11	2	

Note: A trial may fit into more than one categories; N=173 refers to the unique count of reviewed trials.

To see the Impact Analysis of the Portfolio click [here](#)

Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time

Portfolio Approval Process Timeline¹

Calendar Year	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2015	89	24	8
2016	70	24	6
2017	45	19	6
2018	46	21	6
2019 (Jan-Aug)	36	24	0

Facilitated Peer Review (FPR) Process²

Calendar Year	# Applications Completed	Average FPR Time (days)	Median FPR Time (days)
2015	6	47	39
2016	10	98	79
2017	4	79	74
2018	10	84	78
2019	9	74	72

1 from application received to approve/decline the application for period, Jan 13, 2015 to August 31, 2019;

2 from start of peer review to date (i.e. site agreed to pursue peer review) to last reviewer submitted completed peer review package to 3CTN (approved trials only).

Additional links to Portfolio Application Interactive reports:

[Portfolio Application Overview](#)

[Portfolio Application Efficiency Metrics](#)

Appendix: Additional Notes

Table: Study Impact Criteria Definitions

Impact Assessment	Impact Category	Proposed Definition
Trial categories of special interests	Novel Therapy	Trials involving newly developed intervention (e.g. drug, novel biomarker or diagnosis)
	Rare Cancer Setting	As defined by the National Cancer Institute Cancer Facts and Figures 2017, cancer that occurs in <15 out of 100,000 people each year (e.g. mesothelioma, nasopharynx, gallbladder, soft tissue)
	Patient Management	Patient education, awareness, self- assessment trials, symptom control, improving patient experience
	Vulnerable Populations	Pediatric, AYA, elderly, organ dysfunction
	Lifestyle Interventions	Trials focused on lifestyle changes that may prevent, decrease severity and/or delay disease progression and treatment side effects (e.g. exercise, diet)
	Precision Medicine	Biomarker, immunotherapy, diagnosis, and targeted therapies
Potential Impact on Patient Population	Breakthrough Trial	Trial involving a first in class, or novel intervention (drug, biologic, technology or technique) that could dramatically change how people with a particular type of cancer are treated
	Platform Trial	Using already available (e.g. FDA approved) interventions for new combination, new types, settings or stages of cancer
	Enhancement/ Derivative Trial	Using additional targeting biomarker screening to tailor treatment and investigate outcomes (question should this also include imaging enhanced treatment)
	Sustaining Trial	Calibrating/focusing on dosages, treatment cycles or schedule (e.g. colon cancer adjuvant 3 - 6 months)
	Cross Cancer Trial	Results applied to multiple disease sites or basket/umbrella trials
Innovativeness of Trials	Incremental	Potential for iterative changes/advancement (e.g. next in class drugs)
	Paradigm Shifting	Potential for radical improvements in cancers/policy changes within cancer, or across a cancer spectrum (e.g. first in class drugs in phase III trials; introduction of new previously unused intervention or approach; first trials of OncotypeDx in local breast cancer that transformed patient management; first immunotherapy trials)
Study Results	Positive/Negative	Bases on comparison of published results with the study primary outcome/end points